KWM
IMNP

Kingsview Wealth Management’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Kingsview Wealth Management’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-500
Closed -$1K – 403
2017
Q1 		$1K Buy
+500
New +$1.8K ﹤0.01% 302

Other funds holding IMNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kingsview Wealth Management's IMNP Position: Q2 2017 in Review

Kingsview Wealth Management sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2017, closing a stake of 500 shares — an estimated $1K sold.

Kingsview Wealth Management first reported a position in IMNP in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 18 funds tracked by Wall St. Rank hold IMNP as of Q2 2017.

  • Kingsview Wealth Management reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • Kingsview Wealth Management sold 500 Immune Pharmaceuticals Inc. shares in Q2 2017, an estimated $1K.
  • Kingsview Wealth Management first reported a position in Immune Pharmaceuticals Inc. in Q1 2017 and held it in 1 quarter.
  • Kingsview Wealth Management's Immune Pharmaceuticals Inc. position peaked at $1K in Q1 2017.
  • 18 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2017.

Based on Kingsview Wealth Management's 13F filing for Q2 2017, filed 29 Jan 2020.